Natalie Arnold: Biomarkers and the Hidden Burden of CHD
Natalie Arnold, Preventive Cardiologist at University Heart and Vascular Center Hamburg, shared a post on LinkedIn about a recent article she and her colleagues co-authored, published in American Journal of Preventive Cardiology, adding:
“These are challenging times for preventive cardiology: two long-awaited randomized CVOTs – one targeting Lp(a), the other IL-6 mediated inflammation – did not meet their primary CV endpoints.
But neutral treatment trials do not make these biomarkers irrelevant.
They remind us that identifying risk does not automatically tell us how to modify it.
In our new study (just accepted by the American Journal of Preventive Cardiology) we measured Lp(a), hsCRP, and triglycerides in individuals classified as low risk by traditional measures.
The message is simple: the more biomarkers were elevated, the higher the observed CHD risk.
However, individuals classified as low risk but with two or three elevated biomarkers reached absolute event rates comparable to those with multiple conventional risk factors but fewer elevated biomarkers.
Why does this matter?
Low-risk individuals represent a large segment of the population and often remain outside our prevention radar, although they can collectively account for nearly one-third of incident CHD events.
The next challenge is to determine which part of this residual burden is truly modifiable, and in whom…”
Title: Incident coronary heart disease, residual risk and traditional cardiovascular risk factors in the community: The role of the lipid-inflammatory axis
Authors: Natalie Arnold, Christina Magnussen, Jessica Weimann, Alina Goßling, Fabian J. Brunner, Marco M. Ferrario, Paolo Brambilla, Giancarlo Cesana, Valerio Leoni, Luigi Palmieri, Chiara Donfrancesco, Teresa Padró, Jonas Andersson, Pekka Jousilahti, Francisco Ojeda, Tanja Zeller, Allan Linneberg, Stefan Söderberg, Licia Iacoviello, Francesco Gianfagna, Susana Sans, Giovanni Veronesi, Barbara Thorand, Annette Peters, Hugh Tunstall-Pedoe, Frank Kee, Veikko Salomaa, Renate B. Schnabel, Kari Kuulasmaa, Stefan Blankenberg, Raphael Twerenbold, Wolfgang Koenig
Stay updated with Hemostasis Today.
-
Oct 24, 2026, 16:42Mark-Anthony Johnson: Blood Type Awareness and Emergency Transfusion
-
Oct 24, 2026, 16:27Pedro Perez: Florida’s Push to Strengthen VTE Prevention
-
Oct 24, 2026, 16:23Kathleen Freson: Human Cell Models Advance Research into Rare Platelet Disorders
-
Oct 24, 2026, 16:18Victor Daniel: Deep Learning for Automated Platelet Classification
-
Oct 24, 2026, 16:08Paula Alonso-Frías: Human Umbilical Cord Blood Platelet-Rich Plasma for Endometrial Regeneration
-
Oct 24, 2026, 16:00Fatma Ebeid: Ain Shams University Hosts TIF Experts for Collaborating Center Evaluation
-
Oct 24, 2026, 15:52Mazen A. Juratli: Platelet-Derived Extracellular Vesicles as Potential Predictors of Survival in Liver Cancer
-
Oct 24, 2026, 14:28Satyam Arora: Umbilical Cord Blood for Neonatal Transfusions
-
Oct 24, 2026, 13:24Amelia Carro Hevia: Ischaemic Stroke Risk in Atrial Flutter vs Atrial Fibrillation